Art. -Nr.: HY-10580

GSK 3 Inhibitor IX

(Synonyms: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052)

17 Cited Publications

Kundenbewertung

Based on 17 publication(s) in Google Scholar

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC₅₀s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.47%
CAS. Nr.: 667463-62-9
Formel: C₁₆H₁₀BrN₃O₂
Molecular Weight:356.17

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

GSK 3 Inhibitor IX Chemical Structure

CAS. Nr.: 667463-62-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (17)
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

GSK-3α

5 nM (IC₅₀)

GSK-3β

5 nM (IC₅₀)

CDK5/p35

80 nM (IC₅₀)

Cdk1/cyclin B

320 nM (IC₅₀)

cdk2/cyclin A

300 nM (IC₅₀)

Cdk4/cyclin D1

10 μM (IC₅₀)

MAPKK

10 μM (IC₅₀)

protein kinase Cα

12 μM (IC₅₀)

Alle GSK-3 Isoform-spezifische Produkte anzeigen :

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	5.2 μM Compound: 17	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19783149]
HepG2	IC₅₀	5.3 μM Compound: 3b	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay	[PMID: 28743492]
HL-60	IC₅₀	5.4 μM Compound: 17	Antiproliferative activity against human HL60 cells after 5 days by MTT assay Antiproliferative activity against human HL60 cells after 5 days by MTT assay	[PMID: 19783149]
Huh-7	IC₅₀	6.2 μM Compound: 17	Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay	[PMID: 19783149]
IMR-90	IC₅₀	1.9 μM Compound: 17	Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay	[PMID: 19783149]
K562	IC₅₀	1.3 μM Compound: 17	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 19783149]
Monocyte	IC₅₀	>3 μM Compound: 15, 6BIO	Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-8 expression Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-8 expression	[PMID: 24697244]
Monocyte	IC₅₀	0.2 μM Compound: 15, 6BIO	Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-1beta expression Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-1beta expression	[PMID: 24697244]
Monocyte	IC₅₀	0.5 μM Compound: 15, 6BIO	Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced TNFalpha expression Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced TNFalpha expression	[PMID: 24697244]
Monocyte	IC₅₀	1.6 μM Compound: 15, 6BIO	Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-6 expression Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-6 expression	[PMID: 24697244]
Oocyte	IC₅₀	0.32 μM Compound: 53	Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis	[PMID: 34161865]
Oocyte	IC₅₀	0.32 μM Compound: 6-bromoindirubin-3'-oxime	Inhibitory activity against cyclin dependent kinase 1-cyclinB from starfish (Marthasterias glacialis) oocytes Inhibitory activity against cyclin dependent kinase 1-cyclinB from starfish (Marthasterias glacialis) oocytes	[PMID: 14761195]
Sf9	IC₅₀	0.014 μM Compound: BIO	Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay	[PMID: 30234987]
Sf9	IC₅₀	0.041 μM Compound: BIO	Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay	[PMID: 30234987]
Sf9	IC₅₀	0.27 μM Compound: BIO	Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay	[PMID: 30234987]
Sf9	IC₅₀	0.45 μM Compound: BIO	Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay	[PMID: 30234987]
Sf9	IC₅₀	0.527 μM Compound: BIO	Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay	[PMID: 30234987]
Sf9	IC₅₀	3.5 μM Compound: BIO	Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay	[PMID: 30234987]
SH-SY5Y	EC₅₀	>30 μM Compound: 15, 6BIO	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability	[PMID: 24697244]
SH-SY5Y	IC₅₀	0.29 μM Compound: 6BIO	Inhibition of GSK3-mediated beta-casein phosphorylation in human SH-SY5Y cells in presence of MG132 by Western blot analysis Inhibition of GSK3-mediated beta-casein phosphorylation in human SH-SY5Y cells in presence of MG132 by Western blot analysis	[PMID: 18816110]
SH-SY5Y	IC₅₀	10 μM Compound: 6BIO	Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	13 μM Compound: 6BIO	Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	18 μM Compound: 6BIO	Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	9 μM Compound: 6BIO	Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS reduction assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS reduction assay	[PMID: 18816110]
SH-SY5Y	IC₅₀	9.5 μM Compound: 6BIO	Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay	[PMID: 16854069]

In Vitro

GSK 3 Inhibitor IX (BIO) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC₅₀ of 5 nM for GSK-3α/β, shows > 16-fold selectivity over CDK5.
GSK 3 Inhibitor IX interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos^[1].
In human and mouse embryonic stem cells, GSK 3 Inhibitor IX (BIO) maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. GSK 3 Inhibitor IX (BIO)-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells^[2].
GSK 3 Inhibitor IX (BIO) promotes proliferation in mammalian cardiomyocytes^[3].
GSK 3 Inhibitor IX (BIO) is also a pan-JAK inhibitor, with IC₅₀ values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3, respectively. GSK 3 Inhibitor IX (BIO) selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GSK 3 Inhibitor IX (BIO) (50 mg/kg, p.o.) suppresses melanoma tumor growth in a mouse xenograft model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 667463-62-9
Appearance Solid
Molecular Weight 356.17
Formel C₁₆H₁₀BrN₃O₂
Color Brown to red
SMILES

O/N=C(C1=CC=CC=C1N2)/C2=C3C(NC4=C/3C=CC(Br)=C4)=O
Synonyms

6-Bromoindirubin-3'-oxime; BIO; MLS 2052
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (17)

All Cell Proliferation/Viability AssayIFIn Vivo Efficacy StudyIHCRT-PCRWB

Sort by:

Journal Impact Factor

Cell Res

Derivation of totipotent-like stem cells with blastocyst-like structure forming potential. [Abstract]

2022 Jun;32(6):513-529. PMID: 35508506
Nat Commun

MYG1 drives glycolysis and colorectal cancer development through nuclear-mitochondrial collaboration. [Abstract]

2024 Jun 11;15(1):4969. PMID: 38862489

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 11;15(1):4969. [Abstract]

GSK 3 Inhibitor IX (10 μM; 10 h), a GSK3β inhibitor, inhibited the MYG1-induced phosphorylation of PKM2 in HCT116 cells.
Cell Death Differ

The cross talk of two family members of β-TrCP in the regulation of cell autophagy and growth. [Abstract]

2020 Mar;27(3):1119-1133. PMID: 31406304
Chem Eng J

19 November 2021, 133671.

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Chem Eng J. 19 November 2021, 133671.

GSK 3 Inhibitor IX (BIO) (0.1-40 μg/mL; 24 h) at concentrations ranging from 0.1 to 20 μg/mL enhanced cell viability, and 10 μg/mL BIO had the maximal cytoprotective effect.
J Biomed Sci

SARS-CoV-2 membrane protein recruits PP2A to dephosphorylate the nucleocapsid and promote virion production. [Abstract]

2026 May 15;33(1):51. PMID: 42141450
Neoplasia

Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis. [Abstract]

2022 Dec:34:100839. PMID: 36240645
J Transl Med

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]

2022 Oct 2;20(1):444. PMID: 36184616
Cell Rep

FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. [Abstract]

2020 Jan 14;30(2):497-509.e4. PMID: 31940492
NPJ Regen Med

Cyclic pulsation stress promotes bone formation of tissue engineered laminae through the F-actin/YAP-1/β-Catenin signaling axis. [Abstract]

2021 Sep 6;6(1):51. PMID: 34489466

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: NPJ Regen Med. 2021 Sep 6;6(1):51. [Abstract]

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) (2.0 μM) recovered the expression of Osterix and VEGF-A inhibited by YAP-1 knockdown in MSCs.

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: NPJ Regen Med. 2021 Sep 6;6(1):51. [Abstract]

Treatment with GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) (2.0 μM) reduced the degradation and promoted the nuclear translocation of β-Catenin in the CSFP + YAP1-knockdown MSC.
JCI Insight

Aebp1 loss in osteoprogenitors leads to skeletal defects resembling Ehlers-Danlos Syndrome by diminishing Wnt/β-catenin signaling. [Abstract]

2025 Nov 13:e191606. PMID: 41231548

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: JCI Insight. 2025 Nov 13:e191606. [Abstract]

GSK 3 Inhibitor IX (BIO) (10 mL/kg; i.p.) treatment substantially ameliorated skeletal abnormalities and augmented bone formation in Aebp1^OsxCre mice at P0 and P21.
ACS Biomater Sci Eng

6-Bromoindirubin-3'-oxime Promotes Osteogenic Differentiation of Periodontal Ligament Stem Cells and Facilitates Bone Regeneration in a Mouse Periodontitis Model. [Abstract]

2021 Jan 11;7(1):232-241. PMID: 33320531
Int J Mol Sci

Fluoxetine Repurposing Mitigates Alzheimer's Disease Pathology via the GSK3β-CREB-ADAM10 Axis. [Abstract]

2026 Mar 14;27(6):2676. PMID: 41898539
Aquat Toxicol

Tris(1,3-dichloro-2-propyl) Phosphate Inhibits Early Embryonic Development by Binding to Gsk-3β Protein in Zebrafish. [Abstract]

2023 Jul:260:106588. PMID: 37267805
Mol Cell Endocrinol

Synergistic role of β-catenin1 and 2 in ovarian differentiation and maintenance of female pathway in Nile tilapia. [Abstract]

2016 May 15:427:33-44. PMID: 26948949

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2016 May 15:427:33-44. [Abstract]

Immunohistochemistry analyses of gene expression in the in vitro cultured tilapia ovaries obtained from 20 and 180 dah XX fish. Gonads were collected from 180 dah XX fish and cultured in L15 medium with 30 μg/ml Dkk1. Cyp19a1a remained unchanged in the presence of Dkk1. Dkk1 upregulated Cyp11b2 and Dmrt1 expression, which was abolished by simultaneous treatment with GSK 3 Inhibitor IX (Bio) (15-30 μg/mL). The positive signal corresponds to the brownish color. Dkk1, antagonist of canonical Wnt/β-cat signal pathway; Bio, agonist of canonical Wnt/β-cat signal pathway.

GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2016 May 15:427:33-44. [Abstract]

Real-time PCR analysis of cyp11b2 and dmrt1 expression in the in vitro cultured 180 dah tilapia gonad with Dkk1 (0-50 μg/mL) and with or without GSK 3 Inhibitor IX (Bio) (15-30 μg/mL). Gonads were collected from 180 dah XX fish and cultured in L15 medium with 30 μg/mL Dkk1. Dkk1 upregulated cyp11b2 and dmrt1 expression in a dose dependent manner, which was abolished by simultaneous treatment with Bio.
Mol Immunol

Luteolin attenuates type 2 inflammation in asthmatic mice induced by OVA by regulating IL-33/ST2- GSK3β-M2 macrophage polarization. [Abstract]

2025 Oct:186:1-12. PMID: 40752323
Vet Microbiol

Phosphorylation of T425 and methylation of R426 synergistically regulate IBDV VP1 function and viral replication. [Abstract]

2026 Feb:313:110871. PMID: 41506171
bioRxiv

2025 March 10.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 23 mg/mL (64.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8076 mL

14.0382 mL

28.0765 mL

5 mM

0.5615 mL

2.8076 mL

5.6153 mL

10 mM

0.2808 mL

1.4038 mL

2.8076 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Cell Assay^[1]

COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), GSK 3 Inhibitor IX (BIO) (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches appr 70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000× g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT, mouse anti-phospho-β-catenin, mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

BALB/c mice (at 6-8 weeks old) and immunodeficient NOD/SCID/IL2Rgamma null (NSG) mice (female at 6-8 weeks old) are used in the assay. A2058 human melanoma cells at 5×10⁶ cells in serum free medium are inoculated subcutaneously into the dorsal area of NSG mice to create xenograft model. When tumors become palpable, 6 GSK 3 Inhibitor IX (BIO) or vehicle control is administered via oral gavage once daily at 50 mg/kg body weight. Tumor growth is monitored every other day. Tumor volumes are measured every 3 to 4 days. Tumor volumes are calculated using the formula: 0.5 × (larger diameter) × (small diameter)².

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Meijer L, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2003 Dec;10(12):1255-66. [Content Brief]

[2]. Sato N, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004 Jan;10(1):55-63. Epub 2003 Dec 21. [Content Brief]

[3]. Tseng AS, et al. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol. 2006 Sep;13(9):957-63. [Content Brief]

[4]. Liu L1, et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011 Jun 1;71(11):3972-9 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8076 mL	14.0382 mL	28.0765 mL	70.1912 mL
	5 mM	0.5615 mL	2.8076 mL	5.6153 mL	14.0382 mL
	10 mM	0.2808 mL	1.4038 mL	2.8076 mL	7.0191 mL
	15 mM	0.1872 mL	0.9359 mL	1.8718 mL	4.6794 mL
	20 mM	0.1404 mL	0.7019 mL	1.4038 mL	3.5096 mL
	25 mM	0.1123 mL	0.5615 mL	1.1231 mL	2.8076 mL
	30 mM	0.0936 mL	0.4679 mL	0.9359 mL	2.3397 mL
	40 mM	0.0702 mL	0.3510 mL	0.7019 mL	1.7548 mL
	50 mM	0.0562 mL	0.2808 mL	0.5615 mL	1.4038 mL
	60 mM	0.0468 mL	0.2340 mL	0.4679 mL	1.1699 mL

Keywords

GSK 3 Inhibitor IX

17 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GSK 3 Inhibitor IX

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) GSK 3 Inhibitor IX

Alle GSK-3 Isoform-spezifische Produkte anzeigen

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (17)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GSK 3 Inhibitor IX Related Classifications

HY-10580 Related Classifications